New antibody pair could defeat all SARS-CoV-2 variants

FHS
March 6, 2025
5:03 am

A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep pace with evolving viruses.

Arrowhead’s plozasiran set for FDA review as Tryngolza challenge looms – Pharmaceutical Technology

Plozasiran led to an 80% median reduction in baseline of fasting triglyceride level in a Phase III trial. Image credit: Shutterstock/ peterschreiber.media. The US Food

January 20, 2025

Avenge Bio secures FDA designation for mesothelioma therapy

Micrograph of malignant mesothelioma. Credit: Nephron/ commons.wikimedia.org. Avenge Bio has obtained orphan drug designation from the US Food and Drug Administration (FDA) for its AVB-001

June 16, 2023

Breakthrough study defines ideal interval for immunotherapy and liver transplants

Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new cases and 830,200 deaths were

March 6, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.